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Abstract
Background: Physician-directed pharmaceutical advertising is regulated in the United States by the Food and Drug
Administration (FDA); adherence to current FDA guidelines is unknown. Our objective was to determine adherence rates of
physician-directed print advertisements in biomedical journals to FDA guidelines and describe content important for safe
prescribing.
Methods and Findings: Cross-sectional analysis of November 2008 pharmaceutical advertisements within top U.S.-based
biomedical journals publishing original research. We excluded advertisements for devices, over the counter medications,
and disease awareness. We utilized FDA guideline items identifying unique forms of advertisement bias to categorize
advertisements as adherent to FDA guidelines, possibly non-adherent to at least 1 item, or non-adherent to at least 1 item.
We also evaluated advertisement content important for safe prescribing, including benefit quantification, risk information
and verifiable references. All advertisements were evaluated by 2 or more investigators, with differences resolved by
discussion. Twelve journals met inclusion criteria. Nine contained pharmaceutical advertisements, including 192
advertisements for 82 unique products; median 2 per product (range 1–14). Six ‘‘teaser’’ advertisements presented only
drug names, leaving 83 full unique advertisements. Fifteen advertisements (18.1%) adhered to all FDA guidelines, 41 (49.4%)
were non-adherent with at least one form of FDA-described bias, and 27 (32.5%) were possibly non-adherent due to
incomplete information. Content important for safe prescribing was often incomplete; 57.8% of advertisements did not
quantify serious risks, 48.2% lacked verifiable references and 28.9% failed to present adequate efficacy quantification. Study
limitations included its focus on advertisements from a single month, the subjectivity of FDA guidelines themselves, and the
necessary subjectivity of determinations of adherence.
Conclusions: Few physician-directed print pharmaceutical advertisements adhere to all FDA guidelines; over half fail to
quantify serious risks. The FDA could better protect public health by creating new more objective advertisement guidelines
requiring transparent presentation of basic safety and efficacy information.
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Introduction
Advertising is a crucial component of pharmaceutical industry
marketing around the world and advertising in biomedical
journals is estimated by industry to be its most profitable
marketing strategy [1]. Furthermore, physician exposure to
advertisements has been associated with increased prescribing of
advertised drugs [2]. Beyond marketing, proponents of physician-
directed advertisements, mostly from within the pharmaceutical
industry, emphasize the important role advertisements play in
educating physicians and other prescribers about new drugs [3].
However, critics have raised concerns about the quality of the
information presented in these physician-directed advertisements,
including a focus on relative, not absolute, benefit [3–5] and poor
referencing [6–8]. Although systematic assessments of advertise-
ment content to promote evidence-based prescribing have been
limited [9,10], one previous study found that physician-directed
advertisements did not promote guideline-adherent patient care
[11], and critics have argued that advertising may harm patients
and adversely impact public health [12].
In the United States, the Food and Drug Administration (FDA)
is charged with regulating all pharmaceutical marketing through
its Division of Drug Marketing and Advertising (DDMAC).
However, ensuring advertisement adherence is challenging
and FDA resources dedicated to this task are limited. DDMAC’s
fiscal year 2008 budget of $9 million [13] is dwarfed by the
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While the FDA can require that companies change or remove
non-adherent advertisements, given DDMAC’s size and the
volume of marketing materials it regulates, it would be
unreasonable to expect each individual pharmaceutical advertise-
ment to be reviewed.
Acknowledging this regulatory challenge, the FDA has recently
asked physicians to report non-adherent or misleading advertise-
ments through its ‘‘Bad Ad’’ program, explaining that ‘‘With your
valuable assistance, FDA can be more effective in limiting the
number of misleading promotional messages directed to health
care professionals’’ [15]. This program may prove useful in
identifying grossly misleading advertisements; however there has
been no systematic assessment of the adherence of physician-
directed advertisements to FDA regulations in the last 20 years
[16] and none to current standards, which were last updated in
2001.
Therefore, our objectives were to determine adherence to the
2001 FDA guidelines among current print advertisements directed
at physicians within biomedical journals and to describe content
important for safe prescribing. We performed a cross-sectional
analysis of advertisements for prescription pharmaceuticals in top
biomedical journals published in issues over a single month and
hypothesized that rates of non-adherence to FDA guidelines would
be high and that many advertisements would not present complete
information important for safe prescribing.
Methods
Study Sample
We conducted a cross-sectional analysis of advertisements for
prescription pharmaceuticals in top U.S. biomedical journals. We
included all U.S.-based journals with a Thomson Institute for
Scientific Information impact factor .10 that published original
research. We excluded journals publishing only review articles and
journals without a print edition.
We identified all advertisements for prescription pharmaceuti-
cals published in any issue during November 2008. We excluded
advertisements for devices and over-the counter medications and
those designed to heighten awareness of particular diseases without
mention of disease pharmacotherapy. Multiple different adver-
tisements for the same product were all included but duplicate
advertisements for the same prescription pharmaceutical were
included only once in our sample.
Advertisement Assessment
Our advertisement assessment tool contained 36 items, of which
3 described basic characteristics of the advertised drug (e.g. is the
drug a combination pill?), 4 described basic features of the
advertisement (e.g. are there efficacy claims?), 21 were adapted
from FDA guidelines [16], described below, and 8 related to
advertisement content in support of safe prescribing, described
below (see data collection tool in Figure S1).
Advertisement Assessment: FDA Guidelines
Our advertisement assessment tool included items based on
FDA Prescription Drug Advertising Guidelines.
16FDA guidelines
describe 21 unique items used to classify advertisements as ‘‘false,
lacking in fair balance, or otherwise misleading’’ [16]. We
classified the items covered by these FDA guidelines into four
non-exclusive content domains: drug safety (4 items), drug efficacy
(10 items), references (7 items), and other items, which included
quotes (3 items), statistics (2 items), headlines (1 item), and
photographs (1 item).
Advertisement Assessment: Safe Prescribing and Other
Content
Our assessment tool also included descriptive items and items
related to content important for safe prescribing. Safe prescribing
content items were based on prior literature [5,6,10,15] and
accepted standards for the clinical application of data [17]. These
items focused on the presence of verifiable references and the
quantification of risks and benefits with inclusion of appropriate
efficacy numbers, defined as information adequate to calculate
number needed to treat [17], or survival times in the case of
chemotherapeutic agents. To further clarify the presentation of
risks and benefits, we recorded the presence of a black box
warning for each advertised drug and whether the drug places
patients at risk for death or serious morbidity. In addition, we
categorized advertised drugs into four product types based on
indications for their use in the treatment of conditions related to
cardiovascular/diabetes, psychiatric, hematology/oncology or
other diseases.
Advertisement Review and Evaluation
Prior to initiating our reviews, we examined advertisements
which had received FDA warning letters in 2008 (of which none
was in our sample) to determine the approach of FDA to the
regulations. All advertisements were reviewed between January
and December of 2009. Each advertisement was reviewed by at
least 2 of 3 investigators (DK, SK and JSR) and we attempted to
determine adherence in a way that was slightly more conservative
than the approach of the FDA itself (i.e. less likely to rate
advertisements as non-adherent). During advertisement review, we
referred directly to the FDA language embedded within our
assessment tool (see data collection tool in the Figure S1) and
utilized objective measures when possible. We discussed each item
until consensus was reached and were intentionally conservative
when rating the presence of FDA-described features, erring toward
classifying advertisements as guideline adherent. Table S1
describes our approach to FDA item scoring.
Options for abstraction item responses included ‘‘yes’’ and
‘‘no’’, with additional options of ‘‘not applicable’’ and ‘‘not sure’’
where appropriate. We coded the majority of items based only on
the content of the advertisement as presented in the journal, but
for items related to drug status as a first-line agent we used the
2008 Tarascon Pocket PharmacopoeiaH (Jones and Bartlett;
Sudbury, MA) and for items related to the completeness of
references and drug-associated risk of death or serious morbidity
we searched Medline using the internet site pubmed.gov,
considering only data published before October 2008. To establish
black box warnings, we utilized the internet site blackboxrx.com,
considering only warnings issued prior to October 2008.
Advertisements were categorized as adherent, non-adherent, or
possibly non-adherent to FDA guidelines. Advertisements were
considered adherent if they contained none of the 21 features used
by FDA to classify advertisements as misleading, non-adherent if they
contained one or more of the features used by FDA to classify
advertisements as misleading, and possibly non-adherent if there were
no features clearly defining a misleading ad but at least 1 of those
items for which information was incomplete.
Statistical Analysis
We used descriptive statistics to report rates of advertisement
adherence, non-adherence, and possible non-adherence, overall
and categorized by item content (i.e., safety, efficacy, references,
other) and by pharmaceutical product indication (i.e., cardiovas-
cular/diabetes, psychiatric, hematology/oncology or other). We
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advertisement non-adherence rates. Two reviewers (DK and
JSR) independently reviewed a randomly selected 5% sub-sample
of advertisements in order to measure inter-rater reliability and
agreement beyond chance (kappa). Analyses were performed using
JMP 7.1 (SAS Institute, Inc., Cary, NC). All statistical tests were 2-
tailed and used a type I error rate of 0.05.
Results
Advertisement Sample
Twelve biomedical journals met our inclusion criteria. Three
contained no advertisements for prescription pharmaceuticals
(CA, Journal of the National Cancer Institute and Gastroenter-
ology); 9 contained advertisements that were included in our study:
Annals of Internal Medicine (n=14 advertisements), Archives of
General Psychiatry (n=5), Blood (n=36), Circulation (n=9),
Hepatology (n=2), JAMA (n=10), Journal of the American
College of Cardiology (n=25), Journal of Clinical Oncology
(n=56), and the New England Journal of Medicine (n=35). We
reviewed a total of 193 advertisements published during
November 2008, of which one was a correction of a previous
advertisement and was excluded from further analysis. Our final
sample included 89 unique advertisements for 82 products. Seven
products were represented in 2 unique advertisements each; the
remaining 103 non-unique advertisements were duplicates, with a
median of 2 advertisement appearances per product (range 1–14).
Thirty-six manufacturers advertised products in our sample, with a
median of 3 advertisements (range 1–21) and 2 unique advertise-
ments (range 1–7) per company. Of the 89 unique advertisements,
6 (6.7%) were ‘‘teaser’’ advertisements, presenting only the drug
name without additional content; the remaining 83 (93.3%) were
full advertisements and were the focus of our analysis (Table 1).
Six of the 83 (7.2%) full unique advertisements were for
‘‘combination–pill’’ pharmaceutical products and 18 (21.7%) were
for second line agents. More than half of advertised products
(n=43) had an indication for use for hematology/oncology-related
treatment, 17 for cardiovascular/diabetes-related treatment, 7 for
psychiatric-related treatment and 16 for other indications
(Table 1). Our inter-rater reliability with regard to ratings of
FDA guideline items was excellent, with 90.3% agreement and a
kappa of 0.860.
Adherence to FDA guidelines
Among the 83 unique full advertisements, 15 (18.1%) were fully
adherent to FDA guidelines, 41 (49.4%) were non-adherent to at
least 1 FDA mandated item, and 27 (32.5%) were possibly non-
adherent due to incomplete information (Table 2). Among the 41
advertisements that were non-adherent to at least 1 FDA item, the
mean number of items to which the advertisement was non-
adherent was 1.37 (SD=0.73, range 1–4) and among the 68
advertisements that were non-adherent or possibly non-adherent,
the mean number of items to which the advertisement was non-
adherent or possibly non-adherent was 3.51 (SD=2.62, range 1–
11). Forty (48.2%) advertisements were categorized as possibly
non-adherent due to an absence of verifiable references in support
of efficacy or safety claims. The most common FDA criteria to
which advertisements were non-adherent or possibly non-adherent
are shown in Table 3, with descriptions of specific non-adherent
advertisements.
There were statistically significant differences in non-adherence
rates to FDA guidelines by item content. Nine (10.8%)
advertisements were non-adherent to at least 1 FDA item focused
on safety, whereas 18 (21.7%) advertisements were non-adherent
to at least 1 FDA item focused on efficacy (p=0.06)16 (19.3%) to
at least 1 FDA item focused on references (p=0.13), and 23
(27.7%) to at least 1 FDA item focused on other issues (p=0.006)
(Table 3). Among items focused on other issues, rates of non-
adherence varied (Table 2).
There were statistically significant differences in non-adherence
rates to FDA guidelines by product indication category. Four of 16
(25.0%) advertisements for ‘‘other use’’ pharmaceutical products
were non-adherent to at least 1 FDA item, whereas 26 of 43
(60.5%) advertisements for hematology/oncology products were
non-adherent to at least 1 FDA item (p=0.01), 9 of 17 (52.9%)
advertisements for cardiovascular/diabetes products were non-
adherent to at least 1 FDA item (p=0.10), and 2 of 7 (28.6%)
advertisements for psychiatric products were non-adherent to at
least 1 FDA item (p=0.99).
Safe Prescribing Content
Many advertised drugs in our sample presented potential risks
to patients, with 31 (37.3%) containing black box warnings and 33
(39.8%) placing patients at risk for death or serious morbidity.
However, when evaluating advertisement content important for
safe prescribing, we found that many physician-directed adver-
tisements lacked important information. The majority (n=48;
57.8%) did not quantify serious risks and 24 (28.9%) failed to
present appropriate numbers to quantify benefits. Thirty-six
advertisements (43.4%) referenced ‘‘data on file’’ and 40 (48.2%)
lacked verifiable references, due either to an absence of any
references or to the presence of references only to ‘‘data on file’’ or
the product’s package insert (Table 4).
Discussion
In this study we found that nearly half of physician-directed
advertisements fail to adhere to at least one FDA guideline
regulating content. Physician-directed advertisements contained
bias with regard to a wide variety of issues across content areas
Table 1. Sample Description and Characteristics of Physician-
Directed Print Advertisements Published in High-Impact
Biomedical Journals during November 2008.
. N (%)
Total advertisements reviewed 193
Unique advertisement 89 (46.1)
Duplicate advertisement 104 (53.9)
Unique ‘‘Teaser’’ advertisement
a,b 6 (6.7)
Unique Full Advertisement
a 83 (93)
Characteristic of advertised drugs among
Unique Full Advertisements
c
Combination pill 6 (7.2)
Second line agent 18 (21.7)
Product indication type
c
Hematology/Oncology 43 (51.8)
Cardiovascular/Diabetes 17 (20.5)
Psychiatric 7 (9.4)
Other 16 (19.3)
aAmong 89 unique advertisements.
bProviding only product name.
cAmong 83 full unique advertisements.
doi:10.1371/journal.pone.0023336.t001
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consistently identified for non-adherence. In addition, we found
that advertisements do a poor job of conveying basic information
necessary for safe prescribing, with the majority failing to quantify
serious risks, more than one quarter failing to quantify benefits and
nearly half providing no verifiable references. Our study is the first
in nearly 20 years to provide a systematic assessment of the
adherence of U.S. advertisements to FDA guidance and provides
context to inform the FDA’s new ‘‘bad ad’’ program.
Despite the high rates of FDA non-adherence, the mean
number of biased features in each advertisement was low and most
advertisements we reviewed satisfied the majority of FDA-
guidelines despite a general absence of content important for safe
prescribing. FDA guidelines, though detailed, do not target many
of the ad features most important for providing prescribers with
useful information. For instance, FDA emphasizes avoiding
frankly false information and balancing efficacy and safety
information [19] but does little to encourage the presentation of
useful and accurate information. An advertisement containing no
specific efficacy claim, no quantification of drug safety and no
verifiable references would adhere fully to FDA guidelines, despite
presenting no practical information for clinicians. We found many
such advertisements in our sample; for example an advertisement
for a new chemotherapeutic agent presented the indication, the
claim that it was the first in a new drug class, a vague image, and
safety information with no quantification of effect and no
references.
The expectation that advertisements should inform rational
prescribing by presenting complete drug safety and efficacy
information may be unrealistic since advertisements primarily
serve a marketing function [20] and are not designed to train
physicians to properly prescribe. However, proponents of
physician-directed advertising emphasize the important role
advertisements play in educating physicians and other prescribers
about new drugs [3], and it is clear that advertisements do serve to
influence prescribing by providing information to physicians.
While the majority of physicians deny that advertisements inform
their prescribing [21], marketing research has consistently shown
that journal advertising is the most profitable form of drug
marketing, with an estimated return on investment of $5 for every
dollar spent [1]. Furthermore, in some cases exposure to
physician-directed advertising has been shown to be associated
with less effective, lower quality prescribing decisions [22]. It is
clear that prescribers are ultimately responsible for the safety and
efficacy of drugs they prescribe but few doctors recognize the
extent to which they are influenced [23]. Physicians should ensure
that their prescribing is informed by the clinical literature and not
by marketing materials. However, given the high risk associated
with many advertised drugs, any tendency of advertisements to
encourage inappropriate prescribing may pose dangers to patients.
If FDA is truly committed to improving prescribing and protecting
the health of the public it should demand that content important
for safe and effective prescribing be consistently presented in
physician-directed advertisements.
A major challenge of our study was performing advertisement
evaluations given the subjectivity of the current FDA guidelines.
For instance, the FDA describes that advertisements are
misleading if they use ‘‘a quote or paraphrase out of context to
convey a false or misleading idea’’ or ‘‘headline, subheadline, or
pictoral or other graphic matter in a way that is misleading’’,
without providing explicit definitions. We created objective criteria
for many items but scoring still required subjective determinations.
Our conservative approach to subjective items may have
underestimated the true non-adherence rate of the advertisements
we evaluated, which may explain why the rate of advertisement
non-adherence in our study is lower than the 92% non-adherence
rate demonstrated in a 1990 study of journal advertisements
directed at physicians [15].
There are several other important limitations to our study. First,
we sampled advertisements from a single month in 2008, so we
cannot comment on trends in advertisement characteristics over
time. We focused on high-impact biomedical journals publishing
original research, excluding lower-impact and more narrowly
focused publications and those publishing clinical reviews, which
may also be frequently read among clinicians. We may have
missed important differences in advertisements published in these
other types of publications and we expect the volume of
advertisements to have been greater in these journals. However,
we suspect that major differences in advertising content are
unlikely since pharmaceutical company advertisements are
Table 2. Rates of adherence to FDA guidelines among physician-directed print advertisements in high-impact biomedical journals,
overall by FDA guideline item content.
a
Adherent, No. (%) Non-adherent,
b No. (%) Poss. non-adherent,
c No. (%)
Overall 15 (18.1) 41 (49.4) 27 (32.5)
FDA Guideline Item Content
Safety 58 (69.9) 9 (10.8) 16 (19.3)
Efficacy 39 (47.0) 18 (21.7) 26 (31.3)
References 47 (56.6) 16 (19.3) 20 (24.1)
Other Issues 53 (63.9) 23 (27.7) 7 (8.4)
Quotes (n=2) 1 (50.0) 1 (50.0) 0 (0)
Statistics
d (n=24) 22 (91.7) 0 (0) 2 (8.3)
Headlines (n=80) 67 (83.8) 8 (10.0) 5 (6.3)
Photographs (n=41) 33 (80.5) 8 (19.5) 0
Notes: NA=Non-adherence; RR=Relative Risk; CI=Confidence Interval.
aContent domains were non-exclusively categorized.
bDefined as non-adherent to at least 1 item in the category.
cDefined as no non-adherent items in the category, but a response of ‘‘not sure’’ for at least 1 item in the category.
dIncludes statistical testing and pooling of data questions.
doi:10.1371/journal.pone.0023336.t002
Quality of Pharmaceutical Advertisements
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23336T
a
b
l
e
3
.
T
o
p
3
F
D
A
g
u
i
d
e
l
i
n
e
i
t
e
m
s
t
o
w
h
i
c
h
a
d
v
e
r
t
i
s
e
m
e
n
t
s
w
e
r
e
n
o
n
-
a
d
h
e
r
e
n
t
a
n
d
t
o
p
3
F
D
A
g
u
i
d
e
l
i
n
e
i
t
e
m
s
t
o
w
h
i
c
h
a
d
v
e
r
t
i
s
e
m
e
n
t
s
w
e
r
e
p
o
s
s
i
b
l
y
n
o
n
-
a
d
h
e
r
e
n
t
a
.
F
D
A
G
u
i
d
e
l
i
n
e
I
t
e
m
N
o
n
-
A
d
h
e
r
e
n
t
N
o
.
P
o
s
s
i
b
l
y
N
o
n
-
A
d
h
e
r
e
n
t
N
o
.
(
%
)
C
o
m
b
i
n
e
d
N
o
.
(
%
)
E
x
a
m
p
l
e
M
o
s
t
c
o
m
m
o
n
n o n - a d h e r e n t
i
t
e
m
s
‘
‘
C
o
n
t
a
i
n
s
l
i
t
e
r
a
t
u
r
e
r
e
f
e
r
e
n
c
e
s
o
r
q
u
o
t
a
t
i
o
n
s
t
h
a
t
a
r
e
s
i
g
n
i
f
i
c
a
n
t
l
y
m
o
r
e
f
a
v
o
r
a
b
l
e
t
o
t
h
e
d
r
u
g
t
h
a
n
h
a
s
b
e
e
n
d
e
m
o
n
s
t
r
a
t
e
d
b
y
s
u
b
s
t
a
n
t
i
a
l
e
v
i
d
e
n
c
e
’
’
1
0
(
1
2
.
0
)
1
0
(
1
2
.
0
)
2
0
(
2
4
.
1
)
A
n
a
d
v
e
r
t
i
s
e
m
e
n
t
f
o
r
a
d
r
u
g
f
o
r
l
e
u
k
e
m
i
a
d
i
d
n
o
t
m
e
n
t
i
o
n
d
a
t
a
r
e
l
a
t
e
d
t
o
s
t
a
n
d
a
r
d
o
f
c
a
r
e
d
r
u
g
s
w
h
i
c
h
a
r
e
a
v
a
i
l
a
b
l
e
g
e
n
e
r
i
c
a
l
l
y
.
‘
‘
U
s
e
s
h
e
a
d
l
i
n
e
,
s
u
b
h
e
a
d
l
i
n
e
,
o
r
p
i
c
t
o
r
a
l
o
r
o
t
h
e
r
g
r
a
p
h
i
c
m
a
t
t
e
r
i
n
a
w
a
y
t
h
a
t
i
s
m
i
s
l
e
a
d
i
n
g
’
’
8
(
9
.
6
)
5
(
6
.
0
)
1
3
(
1
5
.
7
)
A
n
a
d
v
e
r
t
i
s
e
m
e
n
t
f
o
r
a
d
r
u
g
f
o
r
a
d
v
a
n
c
e
d
l
u
n
g
c
a
n
c
e
r
d
e
p
i
c
t
s
a
h
e
a
l
t
h
y
-
l
o
o
k
i
n
g
m
a
n
a
p
p
a
r
e
n
t
l
y
w
i
n
d
s
u
r
f
i
n
g
o
n
t
h
e
o
p
e
n
s
e
a
‘
‘
R
e
p
r
e
s
e
n
t
s
o
r
s
u
g
g
e
s
t
s
t
h
a
t
d
r
u
g
d
o
s
a
g
e
s
p
r
o
p
e
r
l
y
r
e
c
o
m
m
e
n
d
e
d
f
o
r
…
c
e
r
t
a
i
n
c
l
a
s
s
e
s
o
f
p
a
t
i
e
n
t
s
o
r
d
i
s
e
a
s
e
(
s
)
a
r
e
s
a
f
e
a
n
d
e
f
f
e
c
t
i
v
e
f
o
r
…
o
t
h
e
r
c
l
a
s
s
e
s
o
f
p
a
t
i
e
n
t
s
o
r
d
i
s
e
a
s
e
s
’
’
8
(
9
.
6
)
0
(
0
)
8
(
9
.
6
)
A
n
a
d
v
e
r
t
i
s
e
m
e
n
t
f
o
r
a
h
y
p
e
r
t
e
n
s
i
o
n
m
e
d
i
c
a
t
i
o
n
w
h
i
c
h
i
s
n
o
t
r
e
c
o
m
m
e
n
d
e
d
i
n
g
u
i
d
e
l
i
n
e
s
a
s
a
f
i
r
s
t
o
r
s
e
c
o
n
d
l
i
n
e
a
g
e
n
t
c
l
a
i
m
s
t
o
b
e
f
i
r
s
t
-
l
i
n
e
f
o
r
p
a
t
i
e
n
t
s
l
i
k
e
l
y
t
o
n
e
e
d
m
o
r
e
t
h
a
n
1
a
g
e
n
t
M
o
s
t
c
o
m
m
o
n
p o s s i b l y
n o n - a d h e r e n t
i
t
e
m
s
‘
‘
U
s
e
s
l
i
t
e
r
a
t
u
r
e
,
q
u
o
t
a
t
i
o
n
s
,
o
r
r
e
f
e
r
e
n
c
e
s
t
h
a
t
p
u
r
p
o
r
t
t
o
s
u
p
p
o
r
t
(
a
)
…
c
l
a
i
m
b
u
t
…
d
o
n
o
t
s
u
p
p
o
r
t
t
h
e
c
l
a
i
m
o
r
h
a
v
e
r
e
l
e
v
a
n
c
e
’
’
4
(
4
.
8
)
2
2
(
2
6
.
5
)
2
6
(
3
1
.
3
)
A
n
a
d
v
e
r
t
i
s
e
m
e
n
t
f
o
r
a
d
r
u
g
f
o
r
h
e
m
a
t
o
l
o
g
i
c
m
a
l
i
g
n
a
n
c
y
c
o
n
t
a
i
n
s
e
f
f
i
c
a
c
y
c
l
a
i
m
s
c
i
t
i
n
g
d
a
t
a
o
n
f
i
l
e
.
T
h
e
c
i
t
e
d
s
t
u
d
y
i
s
n
o
w
p
u
b
l
i
s
h
e
d
a
n
d
h
a
d
a
n
i
n
a
p
p
r
o
p
r
i
a
t
e
c
o
m
p
a
r
i
s
o
n
g
r
o
u
p
,
s
o
i
t
d
o
e
s
n
o
t
t
r
u
l
y
s
u
p
p
o
r
t
t
h
e
e
f
f
i
c
a
c
y
c
l
a
i
m
.
‘
‘
P
r
e
s
e
n
t
s
i
n
f
o
r
m
a
t
i
o
n
f
r
o
m
a
s
t
u
d
y
i
n
a
w
a
y
t
h
a
t
i
m
p
l
i
e
s
t
h
a
t
t
h
e
s
t
u
d
y
r
e
p
r
e
s
e
n
t
s
l
a
r
g
e
r
o
r
m
o
r
e
g
e
n
e
r
a
l
e
x
p
e
r
i
e
n
c
e
w
i
t
h
t
h
e
d
r
u
g
t
h
a
n
i
t
a
c
t
u
a
l
l
y
d
o
e
s
’
’
1
(
1
.
2
)
2
0
(
2
4
.
1
)
2
1
(
2
5
.
3
)
M
u
l
t
i
p
l
e
a
d
v
e
r
t
i
s
e
m
e
n
t
s
w
e
r
e
‘
‘
p
o
s
s
i
b
l
y
n
o
n
-
a
d
h
e
r
e
n
t
’
’
t
o
t
h
i
s
i
t
e
m
b
e
c
a
u
s
e
t
h
e
r
e
w
e
r
e
n
o
v
e
r
i
f
i
a
b
l
e
r
e
f
e
r
e
n
c
e
s
.
‘
‘
C
o
n
t
a
i
n
s
r
e
f
e
r
e
n
c
e
s
…
t
h
a
t
m
i
s
r
e
p
r
e
s
e
n
t
t
h
e
e
f
f
e
c
t
i
v
e
n
e
s
s
o
f
a
d
r
u
g
b
y
f
a
i
l
u
r
e
t
o
d
i
s
c
l
o
s
e
…
i
n
f
o
r
m
a
t
i
o
n
…
c
o
n
c
e
r
n
i
n
g
c
o
n
c
o
m
i
t
a
n
t
t
h
e
r
a
p
y
…
(
o
r
)
p
l
a
c
e
b
o
e
f
f
e
c
t
’
’
5
(
6
.
0
)
1
7
(
2
0
.
5
)
2
2
(
2
6
.
5
)
A
n
a
d
v
e
r
t
i
s
e
m
e
n
t
f
o
r
a
m
e
d
i
c
a
t
i
o
n
f
o
r
p
u
l
m
o
n
a
r
y
h
y
p
e
r
t
e
n
s
i
o
n
h
a
s
c
l
a
i
m
s
f
o
r
w
h
i
c
h
t
h
e
s
u
p
p
o
r
t
i
n
g
d
a
t
a
w
a
s
a
n
o
p
e
n
-
l
a
b
e
l
t
r
i
a
l
;
t
h
u
s
r
e
s
u
l
t
s
m
a
y
b
e
r
e
l
a
t
e
d
t
o
p
l
a
c
e
b
o
e
f
f
e
c
t
.
a
O
t
h
e
r
i
t
e
m
s
h
a
d
i
d
e
n
t
i
c
a
l
r
a
t
e
s
,
s
o
t
h
e
i
t
e
m
w
i
t
h
t
h
e
h
i
g
h
e
s
t
c
o
m
b
i
n
e
d
r
a
t
e
i
s
d
i
s
p
l
a
y
e
d
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
2
3
3
3
6
.
t
0
0
3
Quality of Pharmaceutical Advertisements
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23336generally created for use in many journals, not just the highest-
impact journals. We did not evaluate advertisements presented in
other contexts (e.g. direct mailings to physicians) or other media
(e.g. online). Data on the influence of newer marketing strategies is
limited but journal advertisements appear to remain influential
[24]. In addition, while visual aspects of advertisements may be
highly influential, a full content analysis of advertisement imagery
was beyond the scope of this paper. We did note a few patient
photos which were misleading enough to lead to FDA non-
adherence, but it is likely that other advertisements utilized more
subtle imagery to imply more efficacy or broader patient
applicability; thus our analysis may underestimate the misleading
nature of some advertisements. Further, the items we measured to
evaluate information important for safe prescribing were not
validated, although the importance of quantifying benefits and
risks is generally accepted [18] and the concepts evaluating safe
prescribing are straightforward.
Our findings have important policy implications. The FDA has
demonstrated a desire to improve the quality of pharmaceutical
advertisements, most recently by enlisting doctors to review
advertisements through its ‘‘Bad Ad’’ program. FDA should now
move to update and simplify its guidelines for physician
advertisements to facilitate the review process. Updated FDA
guidelines should be straightforward and objective, and should
include requirements that physician advertisements present clear
risk quantification, absolute benefit information, description of the
appropriate population to receive the drug, and verifiable
references, either to the peer-reviewed published literature or to
studies registered within federally-sponsored internet sites such as
ClinicalTrials.gov in the case of unpublished data. These new
guidelines might be applicable only to physician-directed adver-
tisements, with separate guidance for DTC material, with greater
focus on safety issues. Enforcement would still be necessary, as in
other nations advertisements have failed to adhere to new
straightforward requirements [25]. However, new objective
requirements would serve to enhance prescribing and public
health by improving the quality, accuracy and transparency of
advertisements, simplify at least part of the FDA review process,
and facilitate physician participation in reporting ‘‘bad’’ adver-
tisements.
In conclusion, we found low rates of adherence to FDA
guidelines among physician directed pharmaceutical advertise-
ments and inadequate information for safe prescribing. Advertis-
ing is a form of free speech and is a constitutionally protected right
of industry [26]. However, in keeping with its mission to ‘‘protect
the public health by helping to ensure that prescription drug
information is truthful, balanced, and accurately communicated’’
[27] the FDA can ensure that the information provided in
advertisements leads to safe and effective prescribing on the part of
clinicians. Current FDA guidelines are subjective and challenging
to enforce and do not emphasize transparency and the inclusion of
basic information relevant to prescribing. Increased enforcement
of the current regulations would help improve advertisements, but
the subjectivity of the guidelines presents a substantial barrier. We
are hopeful that an update in FDA regulations, with increased
emphasis on the transparent presentation of basic safety and
efficacy information, might improve the quality of information
provided in physician-directed pharmaceutical advertisements.
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